BPC-157 Compounding Pharmacy FDA and State Board Enforcement History

Print or save as PDFOpens the printable question sheet and your print dialog. No sign-up.

What BPC-157 is, and why it sits outside the approval system

BPC-157 is a synthetic peptide of 15 amino acids, molecular weight about 1419.5 g/mol, described as a fragment of a protein first isolated from human gastric juice [1]. No FDA-approved drug contains it, there is no US Pharmacopeia or National Formulary monograph for it, and FDA's July 2026 review found no approved product containing it in any country it searched [1].

It is made as a free base or as an acetate salt, and FDA treats those as two different bulk substances [1]. Websites sell it as capsules, injections, oral sprays and nasal sprays, some labeled 'for research purposes only and not for human or veterinary use' [1]. FDA notes that none of those products is an FDA-approved drug [1].

The federal enforcement timeline

September 2023 to April 22, 2026: the significant-safety-risk category

FDA placed BPC-157 in category 2 of its interim compounding policies, the group of bulk substances the agency says may present significant safety risks when compounded [6]. FDA's page carries its stated concerns: compounded BPC-157 'may pose risk for immunogenicity for certain routes of administration', may have problems with peptide-related impurities and characterization of the active ingredient, and FDA 'has identified no, or only limited, safety-related information for the proposed routes of administration' [6].

April 22, 2026: moved to 'nominated but withdrawn'

In content dated 04/22/2026, FDA's page lists BPC-157 in a separate 'nominated but withdrawn' table rather than the active safety-risk table [6]. That table holds substances previously in category 2 that were withdrawn by the nominators [6]. The groups that nominated BPC-157 withdrew their nominations; the move was not a finding that the substance is safe [6].

BPC-157 is also in none of the three categories on FDA's list of nominated bulk substances for state-licensed pharmacies and physicians, updated May 14, 2026. Category 1 is the group FDA says it generally will not act against compounders for, if conditions are met, so that policy does not cover BPC-157 [2].

July 23, 2026: the advisory committee vote

The Pharmacy Compounding Advisory Committee took up BPC-157 free base and BPC-157 acetate for ulcerative colitis, the use FDA evaluated [7]. FDA's own reviewers had proposed that the substance not be added to the pharmacy bulks list: it is not well characterized chemically, little is known about its safety and immunogenicity, the evidence that it works for ulcerative colitis was judged insufficient, and several approved drugs already treat that condition [1]. The committee voted in favor of adding it anyway, against the staff recommendation [7][4]. The vote is advice only: BPC-157 is not on the list, and adding it would require formal rulemaking, meaning a proposed rule, a public comment period and a final rule [7][4].

October 28, 2026: the draft enforcement-discretion policy

HHS filed a notice announcing a draft enforcement-discretion policy covering six peptides: BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500. It was scheduled for Federal Register publication on October 30, 2026, with public comments open for two weeks after publication [3][4]. In the notice, HHS says it 'does not intend to take enforcement action' against a state-licensed pharmacy, federal facility or licensed physician compounding with a listed peptide while FDA's list is developed through rulemaking, if the policy's conditions are met [3][4].

Conditions the draft policy sets for BPC-157

The draft policy lists these conditions for BPC-157:

• BPC-157 acetate only, in subcutaneous, intramuscular, oral or topical forms; nasal, rectal and intravenous forms are not listed [4]
• A single active ingredient [4]
• Bulk substance from an FDA-registered manufacturer, with a valid certificate of analysis meeting a peptide testing standard [4]
• A label reading 'This is a compounded drug product. Not for resale.' [4]
• A patient-specific prescription [4]
• Serious adverse events and quality problems reported to FDA MedWatch [4]
• Only an FDA 510(k)-cleared syringe as a co-packaged device [4]
• For oral forms, documentation of adequate bioavailability [4]

What the October 2026 policy does not do

The draft is not an FDA approval and does not put BPC-157 on any list [3][4]. The notice itself says it 'does not establish any rights for any person and is not binding on HHS or the public', and HHS may revisit it, for example if a safety signal or a product quality issue appears [3]. It names state-licensed pharmacies, federal facilities and licensed physicians, not outsourcing facilities, the large registered compounders [3][4]. BPC-157 is not on FDA's list for outsourcing facilities, updated March 21, 2025 [5].

Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before marketing [9].

What FDA has said about the safety behind these decisions

FDA's stated position is that it 'lacks sufficient information to know whether the drug would cause harm when administered to humans' [6]. An FDA search of its adverse-event database through December 4, 2025 turned up 3 reports, all involving injectable BPC-157: injection-site redness and swelling lasting 9 days in a patient who also used compounded thymosin, shortness of breath leading to an emergency room visit with no other detail, and widespread skin and gum darkening that recurred on re-exposure to a BPC-157 plus TB-500 'research' product. FDA said it cannot tell whether BPC-157 caused any of them [1].

In the small human studies FDA reviewed, no serious adverse events were reported, but the studies were short, small and gave limited safety information; in the healthy-volunteer enema studies, the most frequent events were headache and flatulence [1]. FDA concluded there is 'insufficient clinical safety information to characterize the safety profile' of BPC-157, and found no human studies of the peptide given by mouth, subcutaneous injection, nasal spray or skin [1].

FDA also noted animal toxicity signals: in 28-day intramuscular studies, BPC-157 shortened clotting time (aPTT) in rats and prolonged it in dogs, and raised liver enzyme (ALT), glucose and triglyceride levels; longer studies and cancer-risk studies were not available [1].

A 2026 systematic review searched to June 1, 2026 for human studies in orthopaedic and regenerative use and found 3 studies with 30 patients in total, all of poor methodological quality, with certainty of evidence rated very low; the reviewers concluded BPC-157 should not be used clinically outside ethically approved, regulated, high-quality trials [10].

Sport: WADA's Prohibited List

WADA's Prohibited List names BPC-157 in S0, the class for substances with no current approval by any governmental regulatory health authority for human therapeutic use, and states that the class includes 'but not limited to BPC-157'. It is prohibited at all times, in and out of competition [8]. BPC-157 has been named as an example under S0 since the 2022 List and remains named in the 2026 List, in force since January 1, 2026, and in the 2027 List approved September 10, 2026 [8][11][12].